Abstract
Stroke is the third common cause of death and the most common cause of adult disability. Approximately 80% of all strokes are ischemic (brain infarction). The only approved acute therapy is intravenous thrombolysis with tissue plasminogen activator within 3 h of symptom onset but only a small percentage of all ischemic stroke patients can receive this therapy. Therefore, novel therapeutic approaches directed at the pathophysiological mechanisms involved in ischemic brain injury are urgently needed. To this end several experimental stroke models were developed. These models are indispensable for understanding the pathophysiology of brain ischemia and to develop novel drugs and investigative methodology. This review considers the most commonly used ischemic stroke models (including preconditioning models) in rodents emphasizing their advantages and disadvantages. Since none of the models can perfectly simulate human stroke, researchers must interpret experimental findings carefully.
Keywords: Rat, mouse, infarction, brain, ischemia, therapy, ischemic tolerance, magnetic resonance imaging, preconditioning
Current Pharmaceutical Design
Title: Rodent Models of Ischemic Stroke: A Useful Tool for Stroke Drug Development
Volume: 14 Issue: 4
Author(s): Aysan Durukan, Daniel Strbian and Turgut Tatlisumak
Affiliation:
Keywords: Rat, mouse, infarction, brain, ischemia, therapy, ischemic tolerance, magnetic resonance imaging, preconditioning
Abstract: Stroke is the third common cause of death and the most common cause of adult disability. Approximately 80% of all strokes are ischemic (brain infarction). The only approved acute therapy is intravenous thrombolysis with tissue plasminogen activator within 3 h of symptom onset but only a small percentage of all ischemic stroke patients can receive this therapy. Therefore, novel therapeutic approaches directed at the pathophysiological mechanisms involved in ischemic brain injury are urgently needed. To this end several experimental stroke models were developed. These models are indispensable for understanding the pathophysiology of brain ischemia and to develop novel drugs and investigative methodology. This review considers the most commonly used ischemic stroke models (including preconditioning models) in rodents emphasizing their advantages and disadvantages. Since none of the models can perfectly simulate human stroke, researchers must interpret experimental findings carefully.
Export Options
About this article
Cite this article as:
Durukan Aysan, Strbian Daniel and Tatlisumak Turgut, Rodent Models of Ischemic Stroke: A Useful Tool for Stroke Drug Development, Current Pharmaceutical Design 2008; 14 (4) . https://dx.doi.org/10.2174/138161208783497688
DOI https://dx.doi.org/10.2174/138161208783497688 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis
Infectious Disorders - Drug Targets Medical Treatment for Neurocysticercosis: Drugs, Indications and Perspectives
Current Topics in Medicinal Chemistry Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Current Stem Cell Research & Therapy Proteomic Approaches Contributing to the Understanding of Neurodegenerative Diseases: Focus on Alzheimers Disease
Current Proteomics The Hyperforin Derivative IDN5706 Occludes Spatial Memory Impairments and Neuropathological Changes in a Double Transgenic Alzheimers Mouse Model
Current Alzheimer Research New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets Review of Antibiotic and Non-Antibiotic Properties of Beta-lactam Molecules
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets HHT: A Rare Disease with A Broad Spectrum of Clinical Aspects
Current Pharmaceutical Design Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Vaccine Development for Group A Streptococcus Infections and Associated Diseases
Current Drug Targets From Cerebrospinal Fluid Pulsation to Noninvasive Intracranial Compliance and Pressure Measured by MRI Flow Studies
Current Medical Imaging Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Alteration of Isocitrate Dehydrogenase Following Acute Ischemic Injury as a Means to Improve Cellular Energetic Status in Neuroadaptation
CNS & Neurological Disorders - Drug Targets Goal Directed Fluid Therapy
Current Pharmaceutical Design The Neural Tract Between the Hypothalamus and Basal Forebrain in the Ascending Reticular Activating System: A Diffusion Tensor Tractography Study
Current Medical Imaging Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Meet Our Editorial Board Member:
CNS & Neurological Disorders - Drug Targets Regenerative Treatment in Spinal Cord Injury
Current Stem Cell Research & Therapy Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry